ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
ADC Therapeutics 宣佈評估 ZYNLONTA 與 Glofitamab 或 Mosunetuzumab 聯合治療復發/難治性 B 細胞非霍奇金淋巴瘤患者的 LOTIS-7 臨床試驗的最新情況
ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).
ADC Therapeutics SA（紐約證券交易所代碼：ADCT）今天宣佈完成 LOTIS-7 的劑量遞增，這是一項1b期開放標籤臨床試驗，評估ZYNLONTA（隆卡妥昔單抗泰西林-lpyl）與雙特異性抗體格洛菲坦單抗或莫蘇內妥珠單抗聯合治療的復發/難治性B細胞非霍奇金淋巴瘤（r/r B-NLYL）患者 HL）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。